Meropenem-vaborbactam as salvage therapy for ceftazidime-avibactam-resistant klebsiella pneumoniae bacteremia and abscess in a liver transplant recipient

Antimicrobial Agents and Chemotherapy

Volumn 63, Issue 1, 2019, Pages

  Athans, Vasilios ^a   Neuner, Elizabeth A ^a   Hassouna, Habiba ^a   Richter, Sandra S ^a   Keller, George ^a   Castanheira, Mariana ^b   Brizendine, Kyle D ^a   Mathers, Amy J ^c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b JMI LABORATORIES   (United States)

^c UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Carbapenem resistant Enterobacteriaceae; Carbapenemase producing Klebsiella pneumoniae; Ceftazidime avibactam; Klebsiella pneumoniae carbapenemase; Meropenem vaborbactam

Indexed keywords

AVIBACTAM PLUS CEFTAZIDIME; GENTAMICIN; MEROPENEM PLUS VABORBACTAM; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; TIGECYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; BACTERIAL PROTEIN; BETA LACTAMASE; BORONIC ACID DERIVATIVE; CARBAPENEMASE; CEFTAZIDIME; MEROPENEM; MEROPENEM AND VABORBACTAM; OUTER MEMBRANE PROTEIN; SINGLE HETEROCYCLIC RINGS;

ADULT; AFRICAN AMERICAN; ARTICLE; BLOOD CULTURE; BLOOD SAMPLING; BROTH DILUTION; CASE REPORT; CLINICAL ARTICLE; DRUG WITHDRAWAL; END STAGE LIVER DISEASE; FOLLOW UP; GRAFT FAILURE; GRAFT RECIPIENT; HEPATIC ARTERY THROMBOSIS; HEPATOJEJUNOSTOMY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KLEBSIELLA PNEUMONIAE INFECTION; LIVER ABSCESS; LIVER GRAFT; LIVER TOXICITY; LUNG LAVAGE; MALE; MINIMUM INHIBITORY CONCENTRATION; PERSISTENT INFECTION; PRIORITY JOURNAL; RETRANSPLANTATION; ROUX Y ANASTOMOSIS; SALVAGE THERAPY; SUBPHRENIC ABSCESS; TREATMENT OUTCOME; X-RAY COMPUTED TOMOGRAPHY; YOUNG ADULT; ADVERSE EVENT; BACTEREMIA; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; DRUG COMBINATION; DRUG EFFECT; GENETICS; HEPATIC ARTERY; ISOLATION AND PURIFICATION; KLEBSIELLA INFECTION; KLEBSIELLA PNEUMONIAE; LIVER TRANSPLANTATION; METABOLISM; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE; PATHOLOGY; PROCEDURES; THROMBOSIS;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BACTEREMIA; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL PROTEINS; BETA-LACTAMASES; BORONIC ACIDS; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; CEFTAZIDIME; DRUG COMBINATIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HEPATIC ARTERY; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; LIVER TRANSPLANTATION; MALE; MEROPENEM; MICROBIAL SENSITIVITY TESTS; SALVAGE THERAPY; THROMBOSIS; YOUNG ADULT;

EID: 85058914230     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01551-18     Document Type: Article

References (29)

1. Donnenberg MS. 2015. Enterobacteriaceae, p 2503–2517. In Mandell, Douglas, and Bennett’s principles and practice of infectious diseases, 8th ed. Saunders, Philadelphia, PA.
2. Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, Kallen A, Limbago B, Fridkin S. 2013. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010. Infect Control Hosp Epidemiol 34: 1–14. https://doi.org/10.1086/668770.
3. Jacob JT, Laxminarayan R, Beldavs Z, Lynfield R, Kallen AJ, Ricks P, Edwards J, Srinivasan A, Fridkin S, Rasheed JK, Lonsway D, Bulens S, Herrera R, McDonald CL, Patel J, Limbago B, Bell M, Cardo D. 2013. Vital signs: carbapenem-resistant Enterobacteriaceae. Morb Mortal Wkly Rep 62:165–170.
4. Tumbarello M, Trecarichi EM, De Rosa FG, Giannella M, Giacobbe DR, Bassetti M, Losito AR, Bartoletti M, Del Bono V, Corcione S, Maiuro G, Tedeschi S, Celani L, Cardellino CS, Spanu T, Marchese A, Ambretti S, Cauda R, Viscoli C, Viale P. 2015. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multi-centre study. J Antimicrob Chemother 70:2133–2143. https://doi.org/10 .1093/jac/dkv086.
5. Daikos GL, Tsaousi S, Tzouvelekis LS, Anyfantis I, Psichogiou M, Argyro-poulou A, Stefanou I, Sypsa V, Miriagou V, Nepka M, Georgiadou S, Markogiannakis A, Goukos D, Skoutelis A. 2014. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 58:2322–2328. https://doi.org/10.1128/AAC.02166-13.
6. Kitchel B, Rasheed JK, Patel JB, Srinivasan A, Navon-Venezia S, Carmeli Y, Brolund A, Giske CG. 2009. Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: clonal expansion of multilocus sequence type 258. Antimicrob Agents Chemother 53: 3365–3370. https://doi.org/10.1128/AAC.00126-09.
7. van Duin D, Kaye KS, Neuner EA, Bonomo RA. 2013. Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. Diagn Microbiol Infect Dis 75:115–120. https://doi.org/10.1016/j.diagmicrobio.2012.11.009.
8. van Duin D, Lok JJ, Earley M, Cober E, Richter SS, Perez F, Salata RA, Kalayjian RC, Watkins RR, Doi Y, Kaye KS, Fowler VG, Paterson DL, Bonomo RA, Evans S, Antibacterial Resistance Leadership Group. 2018. Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clin Infect Dis 66:163–171. https://doi.org/10.1093/cid/cix783.
9. Shields RK, Chen L, Cheng S, Chavda KD, Press EG, Snyder A, Pandey R, Doi Y, Kreiswirth BN, Hong Nguyen M, Clancy CJ. 2017. Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother 61:e02097-16. https://doi.org/10.1128/AAC.02097-16.
10. Shields RK, Potoski BA, Haidar G, Hao B, Doi Y, Chen L, Press EG, Kreiswirth BN, Clancy CJ, Nguyen MH. 2016. Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis 63:1615–1618. https://doi.org/10.1093/cid/ciw636.
11. Gaibani P, Campoli C, Lewis RE, Volpe SL, Scaltriti E, Giannella M, Pongolini S, Berlingeri A, Cristini F, Bartoletti M, Tedeschi S, Ambretti S. 2018. In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment. J Antimicrob Chemother 73:1525–1529. https://doi.org/10.1093/jac/dky082.
12. KPC-2 -harboring Klebsiella pneumoniae sequence type 307 isolates. Antimicrob Agents Chemother 62:e01201-17. https://doi.org/10.1128/AAC.02101-17.
13. Clinical and Laboratory Standards Institute. 2017. Performance standards for antimicrobial susceptibility testing. CLSI, Wayne, PA.
14. Melinta Therapeutics, Inc. April 2018. Meropenem-vaborbactam (package insert). Melinta Therapeutics, Inc, Lincolnshire, IL.
15. Barnes MD, Winkler ML, Taracila MA, Page MG, Desarbre E, Kreiswirth BN, Shields RK, Nguyen MH, Clancy C, Spellberg B, Papp-Wallace KM, Bonomo RA. 2017. Klebsiella pneumoniae carbapenemase-2 (KPC-2), substitutions at Ambler position Asp179, and resistance to ceftazidime-avibactam: unique antibiotic-resistant phenotypes emerge from -lactamase protein engineering. mBio 8:e00528–e00517.
16. Compain F, Arthur M. 2017. Impaired inhibition by avibactam and resistance to the ceftazidime-avibactam combination due to the D179Y substitution in the KPC-2 -lactamase. Antimicrob Agents Chemother 61:e00451-17. https://doi.org/10.1128/AAC.00451-17.
17. Shields RK, Nguyen MH, Chen L, Press EG, Kreiswirth BN, Clancy CJ. 2018. Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant Enterobacteriaceae infections. Antimicrob Agents Chemother 62:e02497-17. https://doi.org/10.1128/AAC.02497-17.
18. Winkler ML, Papp-Wallace KM, Bonomo RA. 2015. Activity of ceftazidime/ avibactam against isogenic strains of Escherichia coli containing KPC and SHV beta-lactamases with single amino acid substitutions in the Omega-loop. J Antimicrob Chemother 70:2279 –2286. https://doi.org/10.1093/jac/dkv094.
19. KPC-3 that confer ceftazidime-avibactam resistance encode novel KPC-3 variants that function as extended-spectrum -lactamases. Antimicrob Agents Chemother 61:e02534-16. https://doi.org/10.1128/AAC.02534-16.
20. Pfaller MA, Huband MD, Mendes RE, Flamm RK, Castanheira M. 3 March 2018. In vitro activity of meropenem-vaborbactam and characterisation of carbapenem-resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem-vaborbactam surveillance programme. Int J Antimicrob Agents https://doi.org/10.1016/j .ijantimicag.2018.02.021.
21. Sun D, Rubio-Aparicio D, Nelson K, Dudley MN, Lomovskaya O. 2017. Meropenem-vaborbactam resistance selection, resistance prevention, and molecular mechanisms in mutants of KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 61:e01694-17. https://doi.org/10.1128/AAC.01694-17.
22. Kaye KS, Bhowmick T, Metallidis S, Bleasdale SC, Sagan OS, Stus V, Vazquez J, Zaitsev V, Bidair M, Chorvat E, Dragoescu PO, Fedosiuk E, Horcajada JP, Murta C, Sarychev Y, Stoev V, Morgan E, Fusaro K, Griffith D, Lomovskaya O, Alexander EL, Loutit J, Dudley MN, Giamarellos-Bourboulis EJ. 2018. Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO 1 randomized clinical trial. JAMA 319:788–799. https://doi.org/10.1001/jama.2018.0438.
23. Kaye KS, Vazquez J, Mathers A, Daikos G, Alexander E, Loutit JS, Zhang S, Dudley MN, Cornely O. 2017. Clinical outcomes of serious infections due to carbapenem-resistant Enterobacteriaceae (CRE) in TANGO II, a phase 3, randomized, multi-national, open-label trial of meropenem-vaborbactam (M-V) vs. best available therapy (BAT). Open Forum Infect Dis 4:S534–S535. https://doi.org/10.1093/ofid/ofx163.1392.
24. Paterson DL, Kwak EJ, Bhowmick T, Alexander E, Loutit JS, Zhang S, Dudley MN, Walsh TJ. 2017. Meropenem-vaborbactam vs. best available therapy for carbapenem-resistant Enterobacteriaceae infections in TANGO II: outcomes in immunocompromised patients. Open Forum Infect Dis 4:S537. https://doi.org/10.1093/ofid/ofx163.1398.
25. Wagenlehner FM, Sobel JD, Newell P, Armstrong J, Huang X, Stone GG, Yates K, Gasink LB. 2016. Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program. Clin Infect Dis 63:754–762. https://doi.org/10.1093/cid/ciw378.
26. Carmeli Y, Armstrong J, Laud PJ, Newell P, Stone G, Wardman A, Gasink LB. 2016. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseu-domonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis 16:661–673. https://doi.org/10.1016/S1473-3099(16)30004-4.
27. Wunderink R, Giamarellos-Bourboulis E, Rahav G, Mathers A, Bassetti M, Solomkin J, Alexander E, Loutit JS, Zhang S, Dudley MN, Kaye KS. 2017. Meropenem-vaborbactam vs. best available therapy for carbapenem-resistant Enterobacteriaceae infections in TANGO II: primary outcomes by site of infection. Open Forum Infect Dis 4:S536–S537. https://doi.org/10.1093/ofid/ofx163.1397.
28. Paul M, Daikos GL, Durante-Mangoni E, Yahav D, Carmeli Y, Benattar YD, Skiada A, Andini R, Eliakim-Raz N, Nutman A, Zusman O, Antonia-dou A, Pafundi PC, Adler A, Dickstein Y, Pavleas I, Zampino R, Daitch V, Bitterman R, Zayyad H, Koppel F, Levi I, Babich T, Friberg LE, Mouton JW, Theuretzbacher U, Leibovici L. 2018. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis 18:391– 400. https://doi.org/10.1016/S1473-3099(18)30099-9.
29. Tsala M, Vourli S, Georgiou PC, Pournaras S, Tsakris A, Daikos GL, Mouton JW, Meletiadis J. 2018. Exploring colistin pharmacodynamics against Klebsiella pneumoniae: a need to revise current susceptibility breakpoints. J Antimicrob Chemother 73:953–961. https://doi.org/10.1093/jac/dkx522.